Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden

Cost Effectiveness and Resource Allocation

Volumn 11, Issue 1, 2013, Pages

  Feldman, Inna ^a,b   Hellström, Lennart ^c   Johansson, Pia ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Smittskyddsenheten   (Sweden)

^c Kalmar County Council   (Sweden)

^d STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Cost effectiveness; Lifestyle counseling; Markov model; Metabolic syndrome; Primary care

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SWEDEN;

EID: 84883284333     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-11-19     Document Type: Article

References (32)

1. Alberti K, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006, 23:469-480.
2. Lauritzen TB-JK, Sandbæk A. Is prevention of type-2 diabetes feasible and efficient in primary care?: a systematic PubMed review. Prim Care Diabetes 2007, 1:5-11. 10.1016/j.pcd.2006.11.001, 18632013.
3. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring) 2009, 17(Suppl 3):S43-S48.
4. Eriksson MK, Franks PW, Eliasson M. A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting: the Swedish Bjorknas study. PLoS One 2009, 4:e5195. 10.1371/journal.pone.0005195, 2664964, 19365563.
5. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005, 142:323-332. 10.7326/0003-4819-142-5-200503010-00007, 2701392, 15738451.
6. Lindgren P, Lindstrom J, Tuomilehto J, Uusitupa M, Peltonen M, Jonsson B, de Faire U, Hellenius ML. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care 2007, 23:177-183.
7. Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia 2010, 53:875-881. 10.1007/s00125-010-1661-8, 20135088.
8. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson EB, Osterlind J, Eliasson M. Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med 2010, 170:1470-1479. 10.1001/archinternmed.2010.301, 20837834.
9. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health 2007, 52:372-382. 10.1007/s00038-007-7014-9, 18369000.
10. Saha S, Gerdtham UG, Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int J Environ Res Public Health 2010, 7:3150-3195. 10.3390/ijerph7083150, 2954575, 20948954.
11. Gillespie P, O'Shea E, Murphy AW, Smith SM, Byrne MC, Byrne M, Cupples ME. Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease. Eur J Health Econ 2012, 13:429-443. 10.1007/s10198-011-0314-2, 21537952.
12. Galani C, Al M, Schneider H, Rutten FF. Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people. Value in Health 2008, 11:424-434. 10.1111/j.1524-4733.2007.00284.x, 18179675.
13. Sculpher M. Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness. Value Health 2010, 13(Suppl 1):S18-S21.
14. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) [http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf].
15. National Institute for Health and Clinical Excellence (NICE) Briefing paper for methods review workshop on identifying sub-groups and exploring heterogeneity [http://www.nice.org.uk/media/4A6/37/SubgroupsBriefingPaper.pdf], National Institute for Health and Clinical Excellence (NICE).
16. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008, 26:799-806. 10.2165/00019053-200826090-00009, 18767899.
17. Engman KO, Feldman I, Hagberg L, Hellström L, Henriksson G, Johansson P. Hälsoekonomisk utvärdering av Metabola projektet i Kalmar län 2008, Kalmar, Sweden: Landstinget i Kalmar Län.
18. Statisics Swdeen [SCB] Living Conditions Survey (ULF/SILC) [http://www.scb.se/Pages/ProductTables.aspx?id=12197], Statisics Swdeen [SCB].
19. Statistics Sweden [SCB] Consumers Price Index (CPI), Harmonized Index of Consumer Prices (2005 = 100) [http://www.scb.se/Pages/TableAndChart_33932.aspx], Statistics Sweden [SCB].
20. Jowett S, Bryan S, Mahe I, Brieger D, Carlsson J, Kartman B, Nevinson M. A multinational investigation of time and traveling costs in attending anticoagulation clinics. Value Health 2008, 11:207-212. 10.1111/j.1524-4733.2007.00253.x, 18380632.
21. Feldman I, Johansson P, Lund C, Jeppsson K. A model for economic evaluations of metabolic syndrome interventions 2011, Technical report (revised 2011) [http://www.folkhalsoguiden.se/ceamodelmetabolic].
22. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30:1374-1383. 2665929, 17363746.
23. Carlsson P, Anell A, Eliasson M. Hälsoekonomi får allt större roll för sjukvårdens prioriteringar [Health economic aspects enhanced role for healthcare priorities]. Lakartidningen 2006, 103:3617-3623.
24. Mahoney EM. Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?. Circulation 2010, 122:1446-1448. 10.1161/CIRCULATIONAHA.110.981944, 20876432.
25. Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment horizontal line using administrative claims data to uncover treatment heterogeneity. J Med Econ 2012, 1:10.
26. Petrou S, Dakin H, Abangma G, Benge S, Williamson I. Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value Health 2010, 13:543-551. 10.1111/j.1524-4733.2010.00711.x, 20345546.
27. Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. BMC Publ Health 2008, 8:201.
28. Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics 2007, 25:807-816. 10.2165/00019053-200725100-00001, 17887803.
29. Brennan A, Akehurst R, Davis S, Sakai H, Abbott V. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 2007, 10:32-41. 10.1111/j.1524-4733.2006.00142.x, 17261114.
30. Assmann S, Pocock S, Enos L, Kasten L. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000, 355:1064-1069. 10.1016/S0140-6736(00)02039-0, 10744093.
31. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Engelgau MM. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care 2007, 30:2874-2879. 10.2337/dc07-0885, 17698614.
32. Caro JJ, O'Brien JA, Hollenbeak CS, Spackman E, Ben-Joseph R, Okamoto LJ, Paramore LC. Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles. Value Health 2007, 10(1):S12-S20.